Hims and Hers stock to expand weight loss program to Canada in 2026

Investing.com - Hims and Hers (NYSE:HIMS), whose stock has surged over 136% in the past year and now commands an $11.1 billion market cap, plans to launch its digital weight loss program in Canada in 2026, coinciding with the expected availability of generic semaglutide in that market.

The telehealth company intends to offer lower-cost alternatives to branded GLP-1 medications, which currently cost over C$200 per month in Canada, through its digital platform. The expansion will follow the same model as its U.S. care offering, which has helped drive impressive revenue growth of 86% over the last twelve months.

This Canadian market entry represents the next step in Hims and Hers’ international expansion strategy, following its recent ZAVA acquisition. The move allows the company to leverage generically-available products in new markets while diversifying its revenue base.

Leerink Partners maintained its Market Perform rating and $42.00 price target on Hims and Hers stock, noting the expansion could serve as an "incremental revenue driver into 2026," though execution and customer uptake will be important factors to monitor.

The company’s current U.S. weight management offerings include personalized semaglutide, generic liraglutide, and oral solutions such as metformin, with the semaglutide product being the most significant driver of current stock debate.

In other recent news, Hims and Hers Health has announced plans to expand into Canada in 2026, aligning with the anticipated availability of generic semaglutide. This expansion is part of the company’s international growth strategy and follows its acquisition of the European digital health platform ZAVA. Meanwhile, Truist Securities has reiterated its Hold rating on Hims and Hers, maintaining a $45.00 price target, citing price increases for compounded semaglutide subscriptions. The price adjustments could be a response to changing trends in the GLP-1 market. In another development, Morgan Stanley (NYSE:MS) has maintained its Equalweight rating and $40.00 price target on Hims and Hers as legal challenges concerning compounded GLP-1 medications continue. The ongoing legal battles could take years to resolve, with potential implications for the company. Furthermore, Truist Securities expressed concerns over Hims and Hers’ revenue projections for 2025, noting potential challenges in meeting full-year guidance. These developments highlight the dynamic and multifaceted environment in which Hims and Hers operates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.